A widely used over-the-counter supplement, frequently turned to by millions of older adults to manage joint pain and support mobility, has been linked to a potentially concerning outcome in individuals already struggling with early cognitive impairment. A new study conducted by researchers at the University of Florida suggests that glucosamine usage is associated with a significantly greater likelihood that mild cognitive impairment (MCI) will progress into full-blown dementia.
The findings, published in the journal Nature Metabolism, represent a significant shift in how scientists are viewing the intersection of metabolic health and neurodegeneration. While the research remains in the preliminary stages and does not definitively prove that glucosamine causes the acceleration of Alzheimer’s disease, the data provides a compelling case for further investigation into how common dietary supplements might inadvertently interfere with the delicate biochemical environment of the aging brain.
A Popular Supplement Under Scrutiny
Glucosamine is a cornerstone of the supplement industry, marketed heavily to older populations as a natural remedy for joint discomfort and the maintenance of cartilage health. Because it is available without a prescription and carries a reputation for safety, it is used by a vast demographic. However, this ubiquity is precisely what prompted researchers to investigate its long-term effects on the brain.
"In the United States, there are about 7 million people living with Alzheimer’s and millions more with related dementias such as Lewy body or frontotemporal dementia," said senior author Ramon Sun, Ph.D., the director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation at the University of Florida’s McKnight Brain Institute. "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse."
The research team, which included experts in biochemistry and molecular biology, sought to determine if the widespread consumption of glucosamine might be influencing the trajectory of Alzheimer’s disease and related dementias (ADRD). To explore this, they utilized sophisticated artificial intelligence tools to analyze deidentified health records from the UF Health system, spanning a 12-year period from 2012 to 2024.
Analyzing the Data: A 25% Increase in Risk
The study’s methodology focused on a specific cohort of patients already diagnosed with either ADRD or MCI—a condition characterized by measurable memory and thinking difficulties that exceed what is expected in normal aging, though they do not yet fully disrupt an individual’s ability to navigate everyday life. Within the records analyzed, approximately 8% of patients in both groups reported the use of glucosamine. This amounted to 1,896 individuals with ADRD and 2,750 people with MCI.
When the researchers adjusted their models to account for confounding factors—such as age, sex, and various demographic variables—the results were stark. Glucosamine use was associated with a 25% higher likelihood that patients with mild cognitive impairment would transition to a formal dementia diagnosis. Furthermore, among the group already diagnosed with ADRD, glucosamine use was linked to a 25% higher mortality risk, suggesting a potential increase in the speed of decline once the disease is established. Notably, this mortality association was not observed in the MCI group, leading researchers to hypothesize that the supplement may have a more pronounced, negative impact once the neurodegenerative process is fully entrenched.
The Role of Metabolic Pathways
While the electronic health record analysis provides a provocative look at the potential risks, the researchers were careful to emphasize that correlation does not equal causation. "The electronic health record data are very provocative," said Matt Gentry, Ph.D., chair of the Department of Biochemistry and Molecular Biology at the University of Florida and a co-author of the study. "While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention."
To bridge the gap between observation and biological proof, the team delved into the molecular mechanisms that might explain why glucosamine could be harmful to a compromised brain. Their research focused on a fundamental metabolic process: the attachment of sugar structures to proteins. While this process, known as glycosylation, is a vital component of normal cellular function, the team discovered that in the context of Alzheimer’s disease, this pathway appears to become hyperactive.
Sun explained that this abnormal metabolic activity could represent an entirely new target for future therapeutic interventions. "Our results suggest that altered metabolism is a significant contributor to Alzheimer’s progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer’s plaques and tangles," Sun noted.
For decades, the scientific community’s understanding of Alzheimer’s has been dominated by the study of amyloid-beta plaques and tau protein tangles. While these remain critical features of the disease, the UF team’s work underscores a growing trend in neuroscientific research: the realization that disrupted metabolism may be a primary driver, rather than a mere secondary symptom, of neurodegeneration.
Advanced Technology Reveals Hidden Pathways
The ability to map these changes was made possible by specialized spatial technology developed in Sun’s laboratory. This equipment allows researchers to observe thousands of molecules simultaneously, providing a high-resolution view of how the body breaks down substances and processes them into hidden biochemical pathways.
The researchers specifically tracked glucosamine, a sugar-related molecule that is capable of crossing the blood-brain barrier—the body’s sophisticated defense system designed to protect the brain from harmful substances in the bloodstream. Once it permeates the brain tissue, glucosamine enters the pathways that build complex sugar structures and attach them to proteins. While this process is standard in healthy brains, the environment within an Alzheimer’s-affected brain is vastly different. The study suggests that the brain’s response to glucosamine is context-dependent, and an Alzheimer’s-damaged brain may be uniquely vulnerable to the influx of this molecule.
From Mice to Human Tissue: Confirming the Mechanism
To test their hypothesis, the team utilized a two-pronged experimental approach. First, they turned to genetically modified mouse models. When these mice were treated with glucosamine, the researchers observed a significant increase in the sugar-tagging of proteins within the cells. Simultaneously, the treated mice exhibited worsened deficits in "social memory"—the ability to recognize other animals—compared to the control group. When the researchers intervened with a chemical treatment to suppress the sugar-tagging process, the memory performance of the mice improved, suggesting that the excessive tagging was a direct contributor to the observed cognitive decline.
Finally, the researchers examined human brain tissue provided by the UF Neuromedicine Brain and Tissue Bank. Collaborating with Stefan Prokop, M.D., the team compared specimens from deceased Alzheimer’s patients with tissue from cognitively normal control subjects. The Alzheimer’s specimens showed a significantly higher degree of sugar attachment, confirming the pattern observed in both the mouse models and the patient health records.
"Proteins are the cell’s molecular machines, and many of them need sugar tags added in just the right way to fold correctly, travel to the right place and do their jobs," Gentry explained. "What we found in Alzheimer’s is that this sugar-tagging system appears to be overactive. The Alzheimer’s brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it."
These findings do not yet provide a clinical directive for patients to immediately cease their use of glucosamine supplements. However, they do underscore the critical need for a controlled human clinical trial to establish whether glucosamine directly accelerates the progression of dementia. Until such data is available, the researchers advise that the medical community and patients alike approach the use of such supplements with increased caution, particularly if there is an existing history of cognitive impairment.
